Vimarsana
Biggest News Aggregation in the World

Page 8 - Boxed Warning News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Boxed Warning. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Boxed Warning Today - Breaking & Trending Today

Legend Biotech's CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma -April 05, 2024 at 11:31 pm EDT - Vimarsana News

Legend Biotech's CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma -April 05, 2024 at 11:31 pm EDT

New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapse ...

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Vimarsana News

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, April 4, 2024 /PRNewswire/ -- Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the...

Vigpoder for Oral Solution Now Available for Refractory CPS, Infantile Spasms - Vimarsana News

Vigpoder for Oral Solution Now Available for Refractory CPS, Infantile Spasms

The prescribing information for Vigpoder carries a Boxed Warning associated with a risk for permanent vision loss.

Source: empr.com
Vafseo Approved for Anemia Due to CKD in Patients on Dialysis - Vimarsana News

Vafseo Approved for Anemia Due to CKD in Patients on Dialysis

The FDA has approved vadadustat for the treatment of anemia due to CKD in adults who have been receiving dialysis for at least 3 months.

FDA approves J&J's OPSYNVI for pulmonary arterial hypertension patients - Vimarsana News

FDA approves J&J's OPSYNVI for pulmonary arterial hypertension patients

In a significant milestone for pulmonary arterial hypertension (PAH) patients, Johnson & Johnson has announced the approval of OPSYNVI.